GRO Biosciences
GRObio’s groundbreaking science expands the amino acid alphabet to deliver on the promise of protein-based therapies.
GRObio’s groundbreaking science expands the amino acid alphabet to deliver on the promise of protein-based therapies.
GRO Biosciences is a pioneering biotech startup founded in 2016 and headquartered in the United States. The company's slogan, "GRObio’s groundbreaking science expands the amino acid alphabet to deliver on the promise of protein-based therapies," encapsulates its mission to revolutionize protein therapeutics. GRO Biosciences is making waves in the Biotechnology and Pharmaceutical industries through its innovative approach, which involves transforming protein therapeutics with new amino acid building blocks to treat incurable diseases. The company recently secured a significant $25.00M Series A investment on 01 November 2021, demonstrating strong investor confidence in its vision and potential. Notable investors in this round include Innovation Endeavors, Redmile Group, Alumni Ventures Blockchain Fund, Digitalis Ventures, and Leaps by Bayer, adding further credibility to GRO Biosciences' growth trajectory. With this recent investment, GRO Biosciences is poised to advance its groundbreaking research and propel the development of novel protein-based therapies with expanded amino acid capabilities.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $60.30M | 6 |
|
19 Jul 2024 |
| Series A | $25.00M | 5 |
|
01 Nov 2021 |
| Grant | $1.20M | 1 |
|
14 Sep 2020 |
| Seed Round | $3.50M | 8 |
|
13 Mar 2019 |
| Grant | $225.00K | 1 |
|
29 Jan 2019 |
No recent news or press coverage available for GRO Biosciences.
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
